Back to top
more

AstraZeneca (AZN)

(Delayed Data from NSDQ)

$79.33 USD

79.33
5,569,039

-2.48 (-3.03%)

Updated Aug 5, 2024 04:00 PM ET

After-Market: $79.34 +0.01 (0.01%) 6:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (72 out of 251)

Industry: Large Cap Pharmaceuticals

Better trading starts here.

Zacks News

AstraZeneca's (AZN) Asthma Drug Benralizumab Approved by FDA

AstraZeneca (AZN) received FDA approval for benralizumab for treating severe eosinophilic asthma.

    Allergan's Vraylar Gets FDA Nod for Maintenance Therapy

    Allergan's (AGN) schizophrenia capsule, Vraylar, secures an FDA approval for its label expansion as a maintenance treatment option in the market.

      Arpita Dutt headshot

      Novo Nordisk & 4 Other Pharma Stocks in Focus on World Diabetes Day

      Despite pricing pressure & competition, the diabetes market remains lucrative given the prevalence of the disease and demand for better treatments. Novo Nordisk (NVO) is a key player in this market.

        AstraZeneca Gets Positive CHMP Opinion for Asthma Candidate

        AstraZeneca (AZN) received CHMP recommendation for marketing approval of its pipeline candidate, benralizumab for treating severe eosinophilic asthma.

          Swarup Gupta headshot

          Foreign Stock Roundup: Toyota, Gol Linhas Beat, AstraZeneca, Fresenius Miss

          Earnings numbers continued to guide Europe's markets last week.

            Arpita Dutt headshot

            Pharma Stock Roundup: AstraZeneca's Q3 Earnings, Roche & Merck Drugs Get FDA Nod

            Key highlights this week include AstraZeneca's (AZN) Q3 results and the FDA approval of the first new CMV medicine in 15 years.

              Valeant (VRX) Earnings and Revenues Beat in Q3, Stock Up

              Valeant (VRX) reported encouraging results for the third quarter but trimmed its guidance to reflect recent divestitures.

                Inovio (INO) Q3 Loss Wider Than Expected, Revenues Miss

                Inovio (INO) reports wider-than-expected loss in Q3. Revenues decline year over year due to lower grants received from DARPA for development of Ebola vaccine.

                  AstraZeneca (AZN) Misses Q3 Earnings, Tweaks 2017 EPS View

                  AstraZeneca's (AZN) Q3 results were mixed. It expects 2017 core earnings to be toward the favorable end of the guidance range of a decline in low-to-mid teen percentage.

                    Arpita Dutt headshot

                    Pharma Stock Roundup: Pfizer, Teva's Q3 Earnings, Novartis Seeks New Indication for Kymriah

                    It was all about earnings last week with companies like Pfizer (PFE), Teva and Allergan reporting third quarter results.

                      Ironwood (IRWD) Beats Estimates in Q3 Earnings, Stock Up

                      Ironwood Pharmaceuticals (IRWD) beats estimates on both counts in the third quarter. Demand for Linzess rises.

                        Clovis (CLVS) Q3 Loss Wider Than Expected, Revenues Miss

                        Clovis (CLVS) witnessed narrower year-over-year loss in the third quarter. Also, the company's revenues missed estimates. Rubraca adoption slower.

                          Incyte Tops Q3 Earnings & Sales, Extends AstraZeneca Deal

                          Incyte Corporation (INCY) reported strong results in the third quarter on strong Jakafi sales and upped its guidance as well.

                            Merck (MRK) Q3 Earnings Top, Sales Lag, Keytruda Stays Strong

                            Merck (MRK) beat estimates for earnings but missed the same for sales in Q3. Despite the sales miss, Merck raised its adjusted earnings guidance for 2017 while increasing its sales guidance marginally.

                              Celgene (CELG) Tops Q3 Earnings, Sales Miss, Updates View

                              Celgene (CELG) beats third-quarter 2017 earnings estimates on the back of robust Revlimid performance.

                                Celgene Down on Discontinued Crohn's Disease Drug Study

                                Shares of Celgene Corporation (CELG) declined after the company announced that a phase III trial, REVOLVE, (CD-002) on pipeline candidate GED-0301 in Crohn's disease and the extension trial, SUSTAIN (CD-004) will be discontinued.

                                  Cancer Treatment Update: Second Gene Therapy Receives Approval

                                  The FDA approved Gilead's Yescarta for DLBCL, second CAR-T therapy in the United States. The regulatory authority also granted priority review to label expansion applications for four major cancer drugs.

                                    AstraZeneca's sNDA for Two Cancer Drugs Gets Priority Review

                                    AstraZeneca (AZN) said that the FDA has granted priority review to its sNDA for two cancer drugs, Lynparza for an advanced breast cancer indication and Imfinzi for an earlier stage of lung cancer.

                                      Bristol-Myers Gets Priority Review for Opdivo Label Expansion

                                      Bristol-Myers (BMY) announced that that the FDA has accepted the supplemental Biologics License Application for priority review of Opdivo to treat patients with melanoma.

                                        Valeant Reports Positive Results on Psoriasis Drug Siliq

                                        Valeant Pharmaceuticals International, Inc. (VRX) announced encouraging results from the long-term phase III extension study, AMAGINE-2 on psoriasis drug Siliq.

                                          Cancer Space Update: Lung & Breast Cancer Studies in Focus

                                          While Lilly announced failure of a lung cancer study, AstraZeneca's Tagrisso was granted Breakthrough therapy status as first-line treatment for a lung cancer indication.

                                            Lilly's Verzenio Gets Priority Review in First-Line Setting

                                            Eli Lilly and Company (LLY) announced that the FDA has granted priority review to its new drug application for Verzenio (abemaciclib) for the first-line treatment of advanced breast cancer.

                                              Clovis (CLVS) Submits sNDA for Ovarian Cancer Drug Rubraca

                                              Clovis submitted a sNDA to the FDA for expansion of Rubraca's label in maintenance treatment for ovarian cancer patients who are in a partial or complete response to platinum-based chemotherapy.

                                                Agilent Boosts Market Share With FDA Nod to New Cancer Test

                                                Agilent Technologies' (A) recent FDA approval for a cancer diagnostic, PD-L1 IHC 28-8 pharmDx for UC and SCCHN patients will further expand its share in the growing cancer-diagnostic market.

                                                  Nektar's Lead Drugs Drive Growth, Partner Reliance a Woe

                                                  Nektar (NKTR) develops several candidates across important therapeutic areas ranging from oncology, pain, anti-infectives to immunology.